SCHEMBL17210488

SCHEMBL17210488

CC(=O)C(CCCCN)NC=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GSR P00390 1/20 0.42
▸ SIRT6 Q8N6T7 1/20 0.41
▸ SIRT1 Q96EB6 1/20 0.41
▸ FOLH1 Q04609 1/20 0.40
▸ GNAI3 P08754 1/20 0.38
▸ GNAO1 P09471 1/20 0.38
▸ GNAI1 P63096 1/20 0.38
▸ SLC6A5 Q9Y345 1/20 0.38
▸ PAOX Q6QHF9 4/20 0.37
▸ RNPEP Q9H4A4 1/20 0.37
▸ CPB2 Q96IY4 2/20 0.37
▸ DPP8 Q6V1X1 1/20 0.36
▸ DPP9 Q86TI2 1/20 0.36
▸ DPP7 Q9UHL4 1/20 0.36
▸ ADH1B P00325 1/20 0.35
▸ ADH1C P00326 1/20 0.35
▸ ADH1A P07327 1/20 0.35
▸ ADH4 P08319 1/20 0.35
▸ ADH7 P40394 1/20 0.35
▸ CA1 P00915 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13218612 0.87 GSR (0.44) GSRSIRT6SIRT1FOLH1GNAI3
SCHEMBL18105654 0.87 GSR (0.44) GSRSIRT6SIRT1FOLH1GNAI3
SCHEMBL19227359 0.84 SIRT6 (0.40) GSRSIRT6SIRT1FOLH1GNAI3
SCHEMBL28786641 0.83 GSR (0.53) GSRFOLH1SLC6A5RNPEPCPB2
SCHEMBL17951698 0.83 ADH1B (0.53) SIRT6SIRT1DPP7ADH1BADH1C
SCHEMBL1168516 0.83 GSR (0.53) GSRFOLH1SLC6A5RNPEPCPB2
SCHEMBL1168511 0.83 GSR (0.53) GSRFOLH1SLC6A5RNPEPCPB2
SCHEMBL23300771 0.82 CPB2 (0.41) GSRSIRT6SIRT1FOLH1GNAI3
SCHEMBL16557197 0.82 GSR (0.40) GSRSIRT6SIRT1FOLH1GNAI3
SCHEMBL14365981 0.82 CPB2 (0.41) GSRSIRT6SIRT1FOLH1GNAI3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021260197-A1 ENHANCED OLIGONUCLEOTIDES FOR MODULATING FUBP1 EXPRESSION F. HOFFMANN-LA ROCHE AG (CH) 2021-12-30 — — WO disclosed
EP-3327027-B9 CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF PFIZER (US) 2021-07-07 — — EP disclosed
EP-3327027-B1 CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF PFIZER (US) 2021-01-06 — — EP disclosed
EP-3327027-A1 CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF Pfizer Inc (US) 2018-05-30 — — EP disclosed
EP-2780039-B9 CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF PFIZER (US) 2018-04-18 — — EP disclosed
EP-2780039-B1 CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF PFIZER (US) 2017-11-29 — — EP disclosed
US-20160213742-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS CIDARA THERAPEUTICS, INC. (US) 2016-07-28 — — US disclosed
WO-2015164289-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS CIDARA THERAPEUTICS, INC. (US) 2015-10-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160213742-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS FPR1, FPR3, FPR2 GSR 1385/4885SIRT6 4495/4885SIRT1 3816/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback